Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Neuroendocrine × pasireotide × Endocrine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroendocrine Tumors 5 Pituitary Neoplasms 4 Gastro-enteropancreatic neuroendocrine tumor 3 Carcinoid Tumor 3 Pituitary ACTH Hypersecretion 2 Acromegaly 2 Serotonin Syndrome 1 Prostatic Neoplasms 1 Prolactin-Producing Pituitary Tumor 1 Pancreatic Neoplasms 1 Neuroectodermal Tumors, Primitive 1 Neoplasms 1 Neoplasm Metastasis 1 Nelson Syndrome 1 Melanoma 1 Lymphoma, Follicular 1 Liver Neoplasms 1 Insulinoma 1 Hypoglycemia 1 Hyperinsulinism 1 Growth Disorders 1 Gigantism 1 Dumping Syndrome 1 Congenital Hyperinsulinism 1 Carcinoma, Neuroendocrine 1 Carcinoma 1 Adrenocortical Hyperfunction 1 Adenoma, Islet Cell 1 ACTH Syndrome, Ectopic 1

Interventions

Cisplatin 11 Everolimus 10 Nivolumab 7 Etoposide 7 Temozolomide 5 Ipilimumab 5 Carboplatin 5 Bevacizumab 5 lutetium Lu 177 dotatate 4 atezolizumab 4 Irinotecan 4 Capecitabine 4 pembrolizumab 3 avelumab 3 Paclitaxel 3 Fluorouracil 3 surufatinib 2 sintilimab 2 gallium Ga 68 dotatate 2 dostarlimab 2 cabozantinib 2 belinostat 2 azaspirane 2 Topotecan 2 Positron Emission Tomography Computed Tomography 2 Magnetic Resonance Imaging 2 Immunoglobulin G 2 IFL protocol 2 Fluorodeoxyglucose F18 2 EC regimen 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01563354 2021-04-02

LUNA

Novartis

Phase 2 Completed

124 enrolled 18 charts

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡